A study looking at the way chemotherapy works in children and young people with B cell non Hodgkin Lymphoma (PK 2005 02)

Cancer type:

Blood cancers
Children's cancers
Non-Hodgkin lymphoma





This study aimed to find out more about the way cyclophosphamide chemotherapy works in children and young people with B cell non Hodgkin Lymphoma.

Cancer Research UK supported this study.

More about this trial

Non Hodgkin lymphoma (NHL) is cancer of the lymphatic system. Chemotherapy is the main treatment for childhood NHL. This can work well, but lymphoma comes back (relapses) in some children and then it becomes more difficult to treat

Cyclophosphamide is one of the chemotherapy drugs used to treat NHL. Research has suggested that there might be a link between how well this drug works and the risk of the lymphoma coming back.

The researchers in this trial wanted to find out more about how cyclophosphamide works in the body once it enters the blood stream. They think there is a reason why it works differently in some children than others. This might be because of their genetic make up and the way their body breaks down and gets rid of the drug.

The aims of the study were to look at

  • how much cyclophosphamide was in the body (pharmacokinetics Open a glossary item)
  • the role of genes Open a glossary item in how the body responded to the drug (pharmacogenetics Open a glossary item)

Summary of results

The researchers found that cyclophosphamide worked differently in the individual children taking part but these differences did not change how well they did.

49 children and young adults took part in the study. They all had B-cell non Hodgkin’s lymphoma and had cyclophosphamide as part of their treatment. 

In total the researchers collected 644 blood samples over 5 years. The samples were taken before and at set times after the children had  cyclophosphamide. 

The length of time it took them to process (metabolise) cyclophosphamide did not influence whether the lymphoma came back (relapsed). 

There were genetic variations between the children and these had a role in how the body processed cyclophosphamide. But again this made no difference to how well the child did in the long term. 

The researchers concluded that this study does not support a link between the way cyclophosphamide is processed and the risk of B-cell non Hodgkins Lymphoma coming back. 

We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr G. Veal
Professor Alan Boddy

Supported by

Cancer Research UK
Children's Cancer and Leukaemia Group (CCLG)
Experimental Cancer Medicine Centre Network
NIHR Clinical Research Network: Cancer
North of England Children’s Cancer Research Fund 
The Newcastle upon Tyne Hospitals NHS Foundation Trust

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:


Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Over 60,000 cancer patients enrolled on clinical trials in the UK last year.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page